PO.MCB08.01 · 分子与细胞生物学

扰动数据缺口:用CRISPR筛选加速发现

The perturbation data gap: Accelerating discovery with CRISPR screening

海报缩略图:扰动数据缺口:用CRISPR筛选加速发现
编号 498 展板 10 时间 4/19 02:00–05:00 区域 Section 20 主讲 Jessica Martyn
分会场 Genomic Dissection to Define Novel Therapeutic Strategies
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Elena Vialetto1, Ronay Cetin1, Sebastian Süsser2, Simran Rastogi1, Angela Hinchie1, Jessica Martyn1, Martin Wegner1, Manuel Kaulich1

1Vivlion GmbH, Frankfurt am Main, Germany,2IBCII, Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany

摘要 Abstract

中文摘要
在Vivlion,我们持续致力于增强CRISPR文库和筛选解决方案。我们推出Alexandria,这是我们的旗舰全基因组PRCISR™ CRISPR敲除文库,提供单靶向和固定配对两种格式。固定配对设计为同一基因(或预定义的基因对)每个细胞递送两个sgRNA,提高编辑效率并支持组合策略。Alexandria通过纳入约1,800个以往试剂忽略的新注释基因来拓宽发现范围,涵盖20,381个基因(约占ENSEMBL的99.8%),每个基因4个sgRNA(2对),以支持在不同细胞类型和状态下的可靠命中判定。 所有PRCISR™文库均采用Vivlion的3Cs技术生产,该技术直接利用寡核苷酸池,避免PCR偏倚和克隆假象,产生高度均一的gRNA分布,即使在缩小规模的筛选(例如有限的原代或iPSC材料)中也能保持代表性。在此基础上,我们的文库格式将序列多样性与分布解耦,因此用户可以根据其生物学需求部署单靶向、固定配对或多重设计。 在实践中,Alexandria使研究人员能够识别情境依赖性依赖关系,探索通路机制、旁系同源基因缓冲,并优先考虑标准筛选可能遗漏的可操作靶点。为简化执行,Vivlion提供合并式和光学合并式筛选、生物信息学支持,并利用我们用于单一和组合CRISPR数据的自动化NGS读数计数流程ReCo,简化下游分析。 通过将先进的CRISPR筛选与Alexandria这样的均一、低覆盖度试剂相结合,研究人员可以在疾病和非疾病背景下同样加速发现。
查看英文原文 English abstract
At Vivlion, we continually strive to enhance CRISPR library and screening solutions. We introduce Alexandria, our flagship genome-wide PRCISR™ CRISPR knockout library, available in single-targeting and fixed-pair formats. The fixed-pair design delivers two sgRNAs per cell for the same gene (or predefined gene pairs), boosting editing efficiency and enabling combinatorial strategies. Alexandria broadens discovery by including ~1,800 newly annotated genes overlooked by previous reagents and covers 20,381 genes (~99.8% of ENSEMBL) with 4 sgRNAs per gene (2 pairs) to support confident hit calling across cell types and states. All PRCISR™ libraries are produced with Vivlion's 3Cs technology, which utilizes the oligo pool directly and avoids PCR bias and cloning artefacts-yielding highly uniform gRNA distributions that preserve representation even in down-scaled screens (e.g., limited primary or iPSC material). Building on this, our library formats decouple sequence diversity from distribution, so users can deploy single-targeting, fixed-pair, or multiplex designs as their biology demands. In practice, Alexandria enables researchers to identify context-dependent dependencies, explore pathway mechanisms, paralog buffering, and prioritise actionable targets that standard screens may miss. To streamline execution, Vivlion offers pooled and optical pooled screening, bioinformatics support, leveraging ReCo, our automated NGS read-counting pipeline for single and combinatorial CRISPR data that simplifies downstream analysis. By combining advanced CRISPR screening with uniform, low-coverage reagents like Alexandria, researchers can accelerate discovery across disease and non-disease contexts alike.
利益披露 Disclosure
E. Vialetto, Vivlion GmbH Other, financial relationship with Vivlion GmbH (employment). R. Cetin, Vivlion GmbH financial relationship with Vivlion GmbH (employment). S. Süsser, None. S. Rastogi, Vivlion GmbH Other, financial relationship with Vivlion GmbH (employment). A. Hinchie, Vivlion GmbH Other, financial relationship with Vivlion GmbH (employment). J. Martyn, Vivlion GmbH financial relationship with Vivlion GmbH (employment). M. Wegner, Vivlion GmbH Other, financial relationship with Vivlion GmbH (employment). M. Kaulich, Vivlion GmbH Other, I am founder, shareholder and employee of Vivlion.

← 返回 AACR 2026 检索